# Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

> **NCT05922501** · PHASE2 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Relapsed Cancer
- Refractory Multiple Myeloma
- Multiple Myeloma

## Interventions

- **DRUG:** Isatuximab
- **DRUG:** Belantamab mafodotin
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05922501
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-31
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05922501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05922501, "Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05922501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*